OncLive

Serum KIM-1 Emerges as Potential Biomarker to Guide Adjuvant Immunotherapy in High-Risk Resected RCC Sumanta Kumar Pal, MD, FASCO, discusses findings from a genomic analysis of patients with high-risk, resected RCC treated with checkpoint inhibitors.

Serum KIM-1 Emerges as Potential Biomarker to Guide Adjuvant Immunotherapy in High-Risk Resected RCC
@cityofhope.bsky.social #kcsm #RCC
www.onclive.com/view/serum-k...

Immunotherapy-Based Trials Challenge Chemotherapy Dominance in MIBC Waddah Arafat, MD, discusses the future clinical implications of the ongoing KEYNOTE-B15/EV-304 trial and the safety profile of the NIAGARA trial regimen.

Immunotherapy-Based Trials Challenge Chemotherapy Dominance in MIBC #oncology

www.onclive.com/view/immunot...

August marks #AppendixCancerAwarenessMonth!
We spoke with Rosario Ligresti, MD, FASGE, about the unexplained rise in incidence of appendix cancer, common misconceptions, and more. @hackensackmeridianhealth.org
Read it all right here:

Investigation of SENTI-202 in R/R AML Continues After Confirming RP2D A dose-expansion cohort will further evaluate SENTI-202 in relapsed/refractory acute myeloid leukemia.

Investigation of SENTI-202 in R/R #AML Continues After Confirming RP2D #oncology

www.onclive.com/view/investi...

FDA Outlines Next Steps for Development of Eftilagimod Alfa in PD-L1–Negative HNSCC The FDA provided feedback on next steps of development for eftilagimod alfa in PD-L1–negative recurrent/metastatic head and neck squamous cell carcinoma.

FDA Outlines Next Steps for Development of Eftilagimod Alfa in PD-L1–Negative #HNSCC

www.onclive.com/view/fda-out...

Gift Launches $200M Initiative for the Weill Cancer Hub West Matching grant from Weill family creates collaborative research hub, uniting scientists from UCSF and Stanford Medicine to transform cancer care within a decade.

Gift Launches $200M Initiative for the Weill Cancer Hub West
@ucsdhealth.bsky.social @ucsfcancer.bsky.social #oncology
www.onclive.com/view/gift-la...

Neoadjuvant Pembrolizumab Could Represent Avenue for Organ Preservation in Nonmetastatic, Unresectable dMMR CRC Neoadjuvant pembrolizumab could represent an avenue for organ preservation in nonmetastatic, unresectable, dMMR colorectal cancer.

Neoadjuvant Pembrolizumab Could Represent Avenue for Organ Preservation in Nonmetastatic, Unresectable dMMR CRC @myesmo.bsky.social #ESMOGI25 #crcsm #oncology
www.onclive.com/view/neoadju...

FDA Grants Priority Review to Liso-Cel for R/R Marginal Zone Lymphoma The FDA granted priority review to a supplemental biologics license application for lisocabtagene maraleucel in relapsed/refractory marginal zone lymphoma.

FDA Grants Priority Review to Liso-Cel for R/R Marginal Zone Lymphoma
@fda.gov #MZL #PriorityReview
www.onclive.com/view/fda-gra...

BXCL701 Plus Pembrolizumab is Safe and Generates Early Antitumor Activity in Advanced PDAC Benjamin A. Weinberg, MD, FACP, discusses the potential role of BXCL701 plus pembrolizumab in advanced pancreatic ductal adenocarcinoma.

BXCL701 Plus Pembrolizumab is Safe and Generates Early Antitumor Activity in Advanced PDAC. #oncology #GIcsm
www.onclive.com/view/bxcl701...

NIAGARA Data Raise Questions About the Role of MVAC in Resectable MIBC Waddah Arafat, MD, discusses the treatment paradigm for MIBC and questions regarding the benefit seen with neoadjuvant chemoimmunotherapy in this setting.

NIAGARA Data Raise Questions About the Role of MVAC in Resectable MIBC
#BladderCancer #blcsm
www.onclive.com/view/niagara...

CaRe Prostate Study of INKmune in Metastatic CRPC Hits Primary, Secondary End Points The phase 1/2 CaRe Prostate trial examining INKmune in patients with metastatic CRPC has met its primary and secondary end points.

CaRe Prostate Study of INKmune in Metastatic CRPC Hits Primary, Secondary End Points
#ProstateCancer #PCSM #Oncology
www.onclive.com/view/care-pr...

Northwell Cancer Institute Names Global Oncology Researcher Geraldine O’Sullivan Coyne, MD, PhD, to lead START Unit’s Early-Stage Clinical Trials Northwell Cancer Institute appointed Geraldine O’Sullivan Coyne, MD, to The START Center for Cancer Research to bring trials to the community setting.

Northwell Cancer Institute Names Global Oncology Researcher Geraldine O’Sullivan Coyne, MD, PhD, to lead START Unit’s Early-Stage Clinical Trials @northwellhealth.bsky.social #oncology
www.onclive.com/view/northwe...

EMA Grants PRIME Designation to BGB-16673 for Previously Treated Waldenström Macroglobulinemia The BTK degrader BGB-16673 has received PRIME designation from the EMA for the treatment of patients with Waldenström macroglobulinemia.

EMA Grants PRIME Designation to BGB-16673 for Previously Treated Waldenström Macroglobulinemia
#WaldenstromMacroglobulinemia #hematology
www.onclive.com/view/ema-gra...

ALPHA3 Trial of Cema-Cel in LBCL Proceeds With Fludarabine/Cyclophosphamide Lymphodepletion Regimen Fludarabine plus cyclophosphamide lymphodepletion will be used in the phase 2 ALPHA3 trial of first-line consolidation cema-cel in patients with LBCL.

ALPHA3 Trial of Cema-Cel in LBCL Proceeds With Fludarabine/Cyclophosphamide Lymphodepletion Regimen #LBCL #lymsm #hematology
www.onclive.com/view/alpha3-...

Dr Shah on Disease-Related Exacerbation With ICIs in Patients With Cancer and Preexisting NAIDs Shailee S. Shah, MD, shares data on the frequency and severity of NAID exacerbation with ICIs in patients with cancer.

WATCH: Shailee S. Shah, MD, shares data on the frequency and severity of NAID exacerbation with ICIs in patients with cancer. @nufeinbergmed.bsky.social @jamanetworkopen.com #OncClub #oncology
www.onclive.com/view/dr-shah...

Retrospective Data Show Feasibility of Checkpoint Inhibition in Patients With Cancer and Neurologic Autoimmune Disorders A retrospective study showed immune checkpoint inhibitors may be an option in appropriate indications for patients with neurologic autoimmune disorders.

Retrospective Data Show Feasibility of Checkpoint Inhibition in Patients With Cancer and Neurologic Autoimmune Disorders @vumedicine.bsky.social @jamanetworkopen.com #oncology
www.onclive.com/view/retrosp...

Casdatifan Plus Cabozantinib Shows Early-Phase Efficacy in Clear Cell RCC Rana R. McKay, MD, FASCO, discusses findings from the ARC-20 trial of casdatifan plus cabozantinib in pretreated clear cell renal cell carcinoma.

Casdatifan Plus Cabozantinib Shows Early-Phase Efficacy in Clear Cell RCC
@ucsdhealth.bsky.social #RCC #kcsm
www.onclive.com/view/casdati...

Consensus Guidelines Needed to Further Optimize PARP Inhibition, Molecular Imaging, and ARPI Use in Prostate Cancer Management Rana R. McKay, MD, expands on key updates and knowledge gaps in prostate cancer management discussed at the Bridging the Gaps in Prostate Cancer meeting.

Consensus Guidelines Needed to Further Optimize PARP Inhibition, Molecular Imaging, and ARPI Use in Prostate Cancer Management
@ucsdhealth.bsky.social #ProstateCancer #PCSM
www.onclive.com/view/consens...

Oral SERDs and PI3K Inhibitors Move the Needle Beyond CDK4/6 Inhibitors in Metastatic Breast Cancer Katherine C. Ansley, MD, discusses the role of oral SERDs and PI3K and AKT inhibitors for the treatment of metastatic breast cancer.

Oral SERDs and PI3K Inhibitors Move the Needle Beyond CDK4/6 Inhibitors in Metastatic Breast Cancer
#BCSM #BreastCancer
www.onclive.com/view/oral-se...

Mayo Clinic Treats First Person in the US With a Novel Radiopharmaceutical Therapy for Breast Cancer Researchers are leading the nation in using powerful and precise radioactive drugs to treat people with complex cancers.

Mayo Clinic Treats First Person in the US With a Novel Radiopharmaceutical Therapy for Breast Cancer @mayocliniccancer.bsky.social #BCSM #Oncology

www.onclive.com/view/mayo-cl...

VT3989 Receives FDA Orphan Drug Designation for Mesothelioma The first-in-class TEAD autopalmitoylation inhibitor VT3989 has received FDA orphan drug designation for the treatment of patients with mesothelioma.

VT3989 Receives FDA Orphan Drug Designation for #Mesothelioma @fda.gov #Oncology
www.onclive.com/view/vt3989-...

Minimally Invasive Surgery and Multidisciplinary Collaboration Improves Recovery Time in Lung Cancer
@hackensackmeridianhealth.org #LCSM #LungCancerAwarenessDay #LungCancer
www.onclive.com/view/minimal...

FDA Issues CRL for Odronextamab in Relapsed/Refractory Follicular Lymphoma The FDA has issued a complete response letter for odronextamab in relapsed or refractory follicular lymphoma.

BREAKING: FDA Issues CRL for Odronextamab in Relapsed/Refractory Follicular Lymphoma #lymsm #oncology www.onclive.com/view/fda-iss...

Following along on the latest #OncChats ☕ series featuring insights from Drs Jason Ye and Daphne B. Stewart of @keckschoolusc.bsky.social? 👀

As a special end-of-month treat, we've released not 1, but 2️⃣ episodes. Be sure to check them out: www.onclive.com/oncchats/coo... #bcsm #oncology

Dr Riedel on the Role of the Multidisciplinary Team in PEComa Management Richard F. Riedel, MD, discusses the importance of multidisciplinary PEComa management and the role of sarcoma specialists in this disease setting.

Richard F. Riedel, MD, of @dukecancer.bsky.social, discusses the importance of multidisciplinary perivascular epithelioid cell tumor (PEComa) management.
Watch now 📺: www.onclive.com/view/dr-ried...

China’s NMPA Accepts Ivonescimab Plus Chemotherapy in Frontline Advanced Squamous NSCLC Ivonescimab plus chemotherapy is under review in China for the frontline treatment of patients with advanced squamous non–small cell lung cancer.

China’s NMPA Accepts Ivonescimab Plus Chemotherapy in Frontline Advanced Squamous #NSCLC

www.onclive.com/view/china-s...

Dr Dietrich on the Efficacy and Safety of Taletrectinib in ROS1+ NSCLC Martin F. Dietrich, MD, PhD, discusses the efficacy and safety profiles of taletrectinib for the management of ROS1-positive non–small cell lung cancer.

Martin F. Dietrich, MD, PhD, of the University of Central Florida, discusses the role of taletrectinib (Ibtrozi) in the treatment of patients with ROS1-positive non–small cell lung cancer (NSCLC).
Watch now 📺: www.onclive.com/view/dr-diet...

Close Collaboration Between Oncology and Neurology Vital in Managing Patients With NAIDs Receiving ICIs for Cancer Shailee S. Shah, MD, discusses the frequency and severity of neurologic autoimmune disorder exacerbation in patients with cancer receiving ICIs.

Close Collaboration Between Oncology and Neurology Vital in Managing Patients With NAIDs Receiving ICIs for Cancer
@nmneurology.bsky.social #Oncology
www.onclive.com/view/close-c...

Forbes Names Roswell Park One of America’s Best Employers for Women 2025
@roswellpark.bsky.social #Forbes #Oncology
www.onclive.com/view/forbes-...

Asciminib Nets Canadian Approval in Newly Diagnosed and Previously Treated Ph+ CML Health Canada has expanded the approval of asciminib to include newly diagnosed and pretreated Ph-positive CML.

Asciminib Nets Canadian Approval in Newly Diagnosed and Previously Treated Ph+ CML
#CML #Hematology #leusm
www.onclive.com/view/ascimin...